EP Patent

EP3448369B1 — Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain

Assigned to University of Colorado System · Expires 2025-06-25 · 1y expired

What this patent protects

Patent listed against chembl-chembl112.

Drugs covered by this patent

Patent Metadata

Patent number
EP3448369B1
Jurisdiction
EP
Classification
—
Expires
2025-06-25
Drug substance claim
No
Drug product claim
No
Assignee
University of Colorado System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.